Concerns Grow Over Melatonin Use in Children Amid Rising Popularity

Melatonin has shown clear benefits for children with neurodevelopmental disorders, but its efficacy in those without such conditions is less established. Researchers express concern about the inconsistent dosing in over-the-counter products, the administration of melatonin without medical supervision, and a rising number of accidental ingestions, underscoring the need for more caution and better regulation.

The increase in sleep difficulties among children and teenagers has sparked heightened interest in melatonin. Poor sleep affects emotional regulation, cognitive development, and overall health, prompting parents to seek quick, convenient options. Melatonin supplements are widely perceived as a safe alternative to prescription medications due to their availability and child-friendly forms.

Despite the general perception of safety, melatonin is a hormone that influences more than just sleep cycles, impacting the immune system, metabolism, and reproductive processes. Current research on the use of melatonin in children is inconsistent; many studies focus on short-term outcomes or specific clinical populations. This inconsistency highlights an urgent need to evaluate the safety and effectiveness of melatonin in pediatric care.

A narrative review from Boston Children's Hospital, published in the World Journal of Pediatrics, investigated the global rise of melatonin use among children. The review analyzed clinical evidence regarding melatonin's effectiveness, safety, and real-world usage patterns. It found a significant discrepancy between the widespread use of melatonin and the limited long-term scientific data available.

Over the past decade, melatonin use among children has sharply increased, particularly in countries where it is available over the counter. Strong evidence supports melatonin's short-term benefits for children with neurodevelopmental disorders like autism and ADHD, helping them fall asleep faster and improving caregivers' overall quality of life.

For typically developing children, research is limited and often inconsistent. Most randomized clinical trials are short-term and tend to focus on older children and adolescents, making it difficult to draw conclusions for younger age groups. Concerns about long-term safety remain, particularly regarding potential impacts on puberty, immune function, metabolism, and neurological development.

The review also pointed out safety issues related to off-label melatonin use. Testing has revealed discrepancies between labeled and actual doses in commercial supplements, with some containing much higher levels than advertised or unexpected substances such as serotonin. Data from pediatric poison control centers shows an increase in accidental ingestions, especially in younger children who may be attracted to gummy formulations that resemble candy.

Experts urge caution, advising that melatonin should not be seen as a quick fix for sleep issues in children. While it can be beneficial in selected cases, guided by health professionals, it should not replace comprehensive sleep assessments or behavioral interventions. Clinicians and caregivers are advised to view melatonin as a biologically active hormone, with potential risks if used unsupervised.

Behavioral strategies should remain the primary treatment for childhood insomnia, including consistent bedtime routines, restricted screen time before bed, and establishing age-appropriate sleep expectations. If melatonin is used, the review recommends starting with the lowest effective dose, limiting treatment duration, and using it under medical supervision. Improved regulation of melatonin products designed for children, clearer labeling, and more long-term research are necessary to ensure safe and effective sleep support for children.